Results 1 to 10 of about 6,893 (130)

Conventional Antiarrhythmics Class I–IV, Late INa Inhibitors, IKs Enhancers, RyR2 Stabilizers, Gap Junction Modulators, Atrial-Selective Antiarrhythmics, and Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Therapy in Arrhythmias [PDF]

Pharmaceuticals
This review examines and hypothesizes cytoprotection as a conceptual therapeutic criterion for antiarrhythmic drugs, referring to the possibility of suppressing arrhythmias while avoiding adverse electrophysiological or systemic effects.
Predrag Sikiric, Ivan Barisic, Mario Udovicic, Martina Lovric Bencic, Diana Balenovic, Dean Strinic, Gordana Zivanovic Posilovic, Sandra Uzun, Hrvoje Vranes, Ivan Krezic, Marin Lozic, Vasilije Stambolija, Ivica Premuzic Mestrovic, Lidija Beketic Oreskovic, Ivana Oreskovic, Sanja Strbe, Suncana Sikiric, Laura Tomic, Mario Kordic, Ante Tvrdeic, Sven Seiwerth, Alenka Boban Blagaic, Anita Skrtic   +22 more
doaj   +2 more sources

Сardioprotective agents with biaromatic structure. Part 2. HCN channel blockers

Фармакокинетика и Фармакодинамика, 2022
Hyperpolarization-activated cyclic nucleotide–gated (HCN) channels, primarily their HCN4 subtype, are one of the promising targets for the development of cardioprotective agents.
G. V. Mokrov
doaj   +1 more source

Сardioprotective agents with biaromatic structure. Part 4. Potassium hERG channels blockers and modulators

Фармакокинетика и Фармакодинамика, 2023
The hERG subtype potassium channel (Kv11.1) is one of the most important and one of the most studied biological targets for the creation of cardioprotective agents.
G. V. Mokrov
doaj   +1 more source

Prenatally diagnosed fetal heart rhythm abnormalities—incidence, diagnosis and outcome

Clinical and Experimental Obstetrics & Gynecology, 2022
Backrounds: Fetal arrhythmias represent a significant cause of fetal morbidity and mortality and occur in approximately 1–3% of pregnancies. The unknown fetal arrhythmias are the cause of intrauterine fetal demise in as many as 3–10% of cases, as well as
Jelena Stamenković, Vojislav Parezanović, Olivera Kontić-Vučinić, Ivan Stefanović, Maja Trkulja, Ida Jovanović, Aleksandar Ljubić, Milena Srbinović   +7 more
doaj   +1 more source

Сardioprotective agents with biaromatic structure. Part 1. Calcium channel blockers

Фармакокинетика и Фармакодинамика, 2022
Cardiovascular diseases (CVD) are widespread and the leading cause of morbidity and mortality worldwide. Drugs for the treatment of CVD have been developed since the beginning of the 20th century.
G. V. Mokrov
doaj   +1 more source

Сardioprotective agents with biaromatic structure. Part 6. Beta blockers

Фармакокинетика и Фармакодинамика, 2023
β-Blockers are one of the oldest classes of cardioprotectors used in the treatment of cardiovascular diseases. They reduce the heart rate, have a hypotensive effect, inhibit myocardial contractility and have antiarrhythmic properties.
G. V. Mokrov
doaj   +1 more source

Medical therapy with flecainide and propafenone in atrial fibrillation: Long-term clinical experience in the tertiary care setting

Cardiology Journal, 2023
BACKGROUND: Flecainide and propafenone are Class Ic antiarrhythmic drugs that block the cardiac fast inwards Na+ current and are used for rhythm control in patients with atrial fibrillation (AF). However, data on long-term clinical efficacy and safety of
Boldizsar Kovacs, Haci Yakup Yakupoglu, Urs Eriksson, Nazmi Krasniqi, Firat Duru   +4 more
doaj   +1 more source

Botulinum Toxin-Chitosan Nanoparticles Prevent Arrhythmia in Experimental Rat Models

Marine Drugs, 2020
Several experimental studies have recently demonstrated that temporary autonomic block using botulinum toxin (BoNT/A1) might be a novel option for the treatment of atrial fibrillation.
David Sergeevichev, Vladislav Fomenko, Artem Strelnikov, Anna Dokuchaeva, Maria Vasilieva, Elena Chepeleva, Yanina Rusakova, Sergey Artemenko, Alexander Romanov, Nariman Salakhutdinov, Alexander Chernyavskiy   +10 more
doaj   +1 more source

Blanking period antiarrhythmic drugs after catheter ablation for atrial fibrillation: a meta-analysis of randomized controlled trials

Frontiers in Cardiovascular Medicine, 2023
BackgroundAntiarrhythmic drugs (AADs) are frequently prescribed following catheter ablation (CA) for atrial fibrillation (AF). However, to date, there is a lack of large-scale, multicenter controlled studies that have confirmed the efficacy of AADs in ...
Gang Chen, Guangling Li, Demei Zhang, Xiaomei Wang, Xueya Guo   +4 more
doaj   +1 more source

Drug-Induced Heart Failure (Part 1: The Urgency of the Problem, the Prevalence, the Effect of Certain Groups of Drugs on the Risk of Development/Progression Heart Failure)

Безопасность и риск фармакотерапии, 2020
Despite all the achievements of modern medicine, heart failure remains one of the most prevalent, severe and prognostically unfavorable conditions that requires close attention of the medical community. The diversity of the clinical picture and the large
O. D. Ostroumova, I. V. Goloborodova
doaj   +1 more source